Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Since the introduction of amyloid imaging nearly ten years ago, this technique has gained widespread use and acceptance. More recently, published reports have begun to appear in which amyloid imaging is used to detect the effects of anti-amyloid therapies. This review will consider the issues involved in the use of amyloid imaging in the development and evaluation of drugs for the treatment of Alzheimer disease. Current evidence regarding the postmortem correlates of in vivo amyloid imaging data is considered. The application of amyloid imaging to screening subjects for trials and use as an outcome measure is discussed in light of longitudinal changes in the in vivo amyloid signal. While the bulk of this review is directed at symptomatic patients with dementia, consideration is given to the use of amyloid imaging in non-demented subjects as well. Similarities and differences of cerebral amyloid assessment by amyloid imaging and CSF measurements are delineated and an agenda for further research to improve the applicability of amyloid PET to clinical trials is proposed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 1×
“…imaging and cognition is due to the fact that Aβ deposition is a very early event in the full spectrum of pathophysiological changes in this disorder and does not necessarily correlate quantitatively with late events like cognition and clinical function [for a review, see (Jack et al., 2010)].”
BackgroundHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 2×
“Most available data seem to indicate that CSF Aβ42 decreases relatively quickly to its final level very early in the course of the pathophysiological spectrum of AD dementia - probably presymptomatically (Blennow and Hampel, 2003; Fagan et al., 2009; Fagan et al., 2007; Hansson et al., 2006).”
BackgroundMitchell, A. J., & Shiri‐Feshki, M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01326.x · Cited by 1,659 · cited 2×
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript concluded that most people with MCI will not progress to dementia even after 10 years of follow-up (Mitchell and Shiri-Feshki, 2009).”
BackgroundHYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 1×
“Most available data seem to indicate that CSF Aβ42 decreases relatively quickly to its final level very early in the course of the pathophysiological spectrum of AD dementia - probably presymptomatically (Blennow and Hampel, 2003; Fagan et al., 2009; Fagan et al., 2007; Hansson et al., 2006).”
BackgroundCorrelation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268 · cited 2×
“…given the fact that typical concentrations of Aβ found in insoluble deposits in AD dementia cortex are ~5,000 µg/L (~1 µM) (Klunk et al., 2005b; Naslund et al., 2000), while typical soluble Aβ concentrations in the cortex are on the order of 50 µg/L (Klunk et al., 2005b) and CSF Aβ…”
BackgroundInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246 · cited 1×
“…in AD dementia cortex are ~5,000 µg/L (~1 µM) (Klunk et al., 2005b; Naslund et al., 2000), while typical soluble Aβ concentrations in the cortex are on the order of 50 µg/L (Klunk et al., 2005b) and CSF Aβ concentrations are ~0.5 µg/L (Fagan et al., 2006) - or 0.01% of insoluble cortical Aβ.”
BackgroundInfluentialSelf-citationUse of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
Self-citationJack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986 · cited 10×
“Rowe et al. studied 177 cognitively normal controls and also found an age effect such that elevated PiB retention was seen in 18% at age 60–69 years and 65% over age 80 (Rowe et al., 2010).”
BackgroundResultInfluentialConsensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981
Jack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958
Self-citationPost-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933 · cited 7×
“In addition, fibrillar Aβ can be found in varying degrees in plaques that have been loosely characterized as “diffuse”, and these diffuse plaques can be detected to some extent by amyloid imaging agents (Burack et al., 2010; Ikonomovic et al., 2008; Lockhart et al., 2007).”
BackgroundInfluentialSelf-citationFagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · cited 1×
“Most available data seem to indicate that CSF Aβ42 decreases relatively quickly to its final level very early in the course of the pathophysiological spectrum of AD dementia - probably presymptomatically (Blennow and Hampel, 2003; Fagan et al., 2009; Fagan et al., 2007; Hansson et al., 2006).”
BackgroundAPOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830
Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789 · cited 10×
“Several studies (3 in controls; 1 in MCI and 3 in AD dementia) have found a significant correlation between PiB and cognition in single diagnostic groups (Darreh-Shori et al., 2010; Engler et al., 2006; Grimmer et al., 2009a; Mormino et al., 2009; Pike et al., 2007; Rentz et al., 2010) - although one of these studies…”
BackgroundInfluentialSelf-citationReiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785 · cited 8×
“However, amyloid imaging in isolation from clinical and cognitive data is poorly suited for the identification of a subject who is likely to receive a clinical diagnosis of MCI, since a roughly equal portion of MCI cases are PiB-positive and PiB-negative.”
BackgroundInfluentialSelf-citationMcKeith, I., O'Brien, J., Walker, Z., Tatsch, K., Booij, J., Darcourt, J., Padovani, A., Giubbini, R., Bonuccelli, U., Volterrani, D., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70057-1 · Cited by 716
Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Self-citationWong, D. F., Rosenberg, P. B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H. T., Dannals, R. F., Nandi, A., Brašić, J. R., Ye, W., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069088 · Cited by 684 · cited 2×
“, 2008)), [F-18]florbetapir (AV-45; (Wong et al., 2010)) and [F-18]flutemetamol (3’F-PiB or GE-067; (Nelissen et al.”
BackgroundDisruption of Functional Connectivity in Clinically Normal Older Adults Harboring Amyloid Burden
Hedden, T., Van Dijk, K. R. A., Becker, J. A., Mehta, A., Sperling, R. A., Johnson, K. A., & Buckner, R. L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3189-09.2009 · Cited by 598
Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's Disease
Mayeux, R., Saunders, A. M., Shea, S., Mirra, S., Evans, D., Roses, A. D., Hyman, B. T., Crain, B., Tang, M.-X., & Phelps, C. H. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802193380804 · Cited by 547 · cited 2×
“…made using standard criteria (McKhann et al., 1984) in the setting of a specialized center such as the Alzheimer Disease Centers in the US has been confirmed by autopsy in over 95% of cases (Mayeux et al., 1998), this number can drop to near 70% in less specialized settings (Knopman et al., 2001).”
MethodResultAmyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study
Edison, P., Archer, H. A., Hinz, R., Hammers, A., Pavese, N., Tai, Y. F., Hotton, G., Cutler, D., Fox, N., Kennedy, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000244749.20056.d4 · Cited by 518
Edison, P., Archer, H. A., Gerhard, A., Hinz, R., Pavese, N., Turkheimer, F. E., Hammers, A., Tai, Y. F., Fox, N., Kennedy, A., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.08.001 · Cited by 513 · cited 2×
“Parkinson’s disease and Parkinson’s dementia are typically well-distinguished from AD dementia with PiB PET (Edison et al., 2008b; Gomperts et al., 2008; Johansson et al., 2008; Maetzler et al., 2008), although mixed cases can occur (Gomperts et al., 2008; Maetzler et al., 2008).”
BackgroundAβ amyloid and glucose metabolism in three variants of primary progressive aphasia
Rabinovici, G. D., Jagust, W. J., Furst, A. J., Ogar, J. M., Racine, C. A., Mormino, E. C., O'Neil, J. P., Lal, R. A., Dronkers, N. F., Miller, B. L., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21451 · Cited by 477
Morris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.269 · Cited by 476
Relationships between biomarkers in aging and dementia
Jagust, W. J., Landau, S. M., Shaw, L. M., Trojanowski, J. Q., Koeppe, R. A., Reiman, E. M., Foster, N. L., Petersen, R. C., Weiner, M. W., Price, J. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc010c · Cited by 456 · cited 5×
“…other later stage biomarkers (e.g., CSF tau protein levels, hypometabolism and brain atrophy) tend to correlate better quantitatively with degree of cognitive impairment than does PiB (Engler et al., 2006; Jack et al., 2009; Jagust et al., 2009; Mormino et al., 2009; Storandt et al., 2009).”
BackgroundInfluentialImaging amyloid deposition in Lewy body diseases
Gomperts, S. N., Rentz, D. M., Moran, E., Becker, J. A., Locascio, J. J., Klunk, W. E., Mathis, C. A., Elmaleh, D. R., Shoup, T., Fischman, A. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000326146.60732.d6 · Cited by 443 · cited 5×
“Parkinson’s disease and Parkinson’s dementia are typically well-distinguished from AD dementia with PiB PET (Edison et al., 2008b; Gomperts et al., 2008; Johansson et al., 2008; Maetzler et al., 2008), although mixed cases can occur (Gomperts et al.”
BackgroundInfluentialSelf-citationMicroglial activation and amyloid deposition in mild cognitive impairment: A PET study
Okello, A., Edison, P., Archer, H. A., Turkheimer, F. E., Kennedy, J., Bullock, R., Walker, Z., Kennedy, A., Fox, N., Rossor, M., et al. (2009) · Neurology · doi:10.1212/01.wnl.0000338622.27876.0d · Cited by 367
Fagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C., & Holtzman, D. M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900048 · Cited by 353
PIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis
Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., Libri, V., Leppert, D., & Beach, T. G. (2007) · Brain · doi:10.1093/brain/awm191 · Cited by 302 · cited 1×
“In addition, fibrillar Aβ can be found in varying degrees in plaques that have been loosely characterized as “diffuse”, and these diffuse plaques can be detected to some extent by amyloid imaging agents (Burack et al., 2010; Ikonomovic et al., 2008; Lockhart et al., 2007).”
BackgroundLongitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [ 11 C]PiB
Resnick, S. M., Sojkova, J., Zhou, Y., An, Y., Ye, W., Holt, D. P., Dannals, R. F., Mathis, C. A., Klunk, W. E., Ferrucci, L., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d3e3e9 · Cited by 288 · cited 9×
“However, amyloid imaging in isolation from clinical and cognitive data is poorly suited for the identification of a subject who is likely to receive a clinical diagnosis of MCI, since a roughly equal portion of MCI cases are PiB-positive and PiB-negative.”
BackgroundInfluentialSelf-citationGrimmer, T., Riemenschneider, M., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Shiga, T., Wester, H.-J., Kurz, A., & Drzezga, A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.027 · Cited by 278 · cited 2×
“One study has suggested that CSF Aβ42 is most tightly correlated with PiB retention in brain regions immediately adjacent to CSF spaces (Grimmer et al., 2009b).”
BackgroundSelf-citationEffect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease
Drzezga, A., Grimmer, T., Henriksen, G., Mühlau, M., Perneczky, R., Miederer, I., Praus, C., Sorg, C., Wohlschläger, A., Riemenschneider, M., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a2e8d0 · Cited by 248
Bourgeat, P., Chételat, G., Villemagne, V. L., Fripp, J., Raniga, P., Pike, K., Acosta, O., Szoeke, C., Ourselin, S., Ames, D., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181c918b5 · Cited by 220 · cited 1×
“…sectional association between clinical diagnosis and amyloid imaging Many studies have reported the results of PiB PET imaging in MCI subjects (Bourgeat et al., 2010; Butters et al., 2008; Cohen et al., 2009; Devanand et al., 2010; Forsberg et al., 2010; Forsberg et al., 2008; Fripp et al.,…”
BackgroundLeinonen, V. (2008) · Archives of Neurology · doi:10.1001/archneur.65.10.noc80013 · Cited by 199 · cited 2×
“In a biopsy study, Leinonen et al. reported “Case #6” with high numbers of plaques by IHC (although sparse neuritic plaques) but a negative PiB scan (Leinonen et al., 2008).”
BackgroundFripp, J., Bourgeat, P., Acosta, O., Raniga, P., Modat, M., Pike, K. E., Jones, G., O'Keefe, G., Masters, C. L., Ames, D., et al. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.07.053 · Cited by 80 · cited 2×
“…MCI subjects (Bourgeat et al., 2010; Butters et al., 2008; Cohen et al., 2009; Devanand et al., 2010; Forsberg et al., 2010; Forsberg et al., 2008; Fripp et al., 2008; Jack et al., 2008; Jack et al., 2009; Jagust et al., 2010; Jagust et al., 2009; Kemppainen et al., 2007; Koivunen et al., 2008;…”
BackgroundDarreh-Shori, T., Forsberg, A., Modiri, N., Andreasen, N., Blennow, K., Kamil, C., Ahmed, H., Almkvist, O., Långström, B., & Nordberg, A. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.028 · Cited by 64
. Pittsburgh compound B binding in poststroke dementia.
Mok, V., Leung, E. Y. L., Chu, W., Chen, S., Wong, A., Xiong, Y., Lam, W., Ho, C. L., & Wong, K. S. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.12.014 · Cited by 52 · cited 1×
“Clinical history and MRI findings should be able to exclude these cases if necessary (Mok et al., 2010).”
Background
Cited by
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Self-citationPrevalence of Amyloid PET Positivity in Dementia Syndromes: A Meta-analysis
Ossenkoppele, R., Jansen, W. J., Rabinovici, G. D., Knol, D. L., van der Flier, W. M., van Berckel, B. N. M., Scheltens, P., Visser, P. J., Verfaillie, S. C. J., Zwan, M. D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4669 · Cited by 677
Self-citationBlennow, K., Brody, D. L., Kochanek, P. M., Levin, H., McKee, A., Ribbers, G. M., Yaffe, K., & Zetterberg, H. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.84 · Cited by 634
Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.002 · Cited by 603
Amyloid biomarkers in Alzheimer's disease
Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470
Metadata
- Authors
- Klunk, W. E.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 32
- Pages
- S20-S36
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2082766755
- Cited by
- 129
- References
- 43
- FWCI
- 11.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.